Crispr Therapeutics AG (CRSP)
CRISPR Therapeutics AG (CRSP) Rises Higher Than Market: Key Facts
The latest trading day saw CRISPR Therapeutics AG (CRSP) settling at $42.94, representing a +2.02% change from its previous close.
CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 3:20 PM ET Company Participants Samarth Kulkarni - CEO & Chairman Conference Call Participants Salveen Jaswal Richter - Goldman Sachs Group, Inc., Research Division Salveen Jaswal Richter Good afternoon. Thank you, everyone, for joining us.
Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CRISPR Therapeutics (CRSP) Up 11.1% Since Last Earnings Report: Can It Continue?
CRISPR Therapeutics (CRSP) reported earnings 30 days ago. What's next for the stock?
Can CRISPR Build on Casgevy's Success With Its In Vivo Pipeline?
CRSP aims to extend its gene-editing lead with in vivo candidates after Casgevy's ex vivo breakthrough success.
CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP ) William Blair's 45th Annual Growth Stock Conference June 3, 2025 12:20 PM ET Company Participants Raju Prasad - Chief Financial Officer Conference Call Participants Sami Corwin - William Blair Sami Corwin Hi, everyone. We're going to get started.
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
CRISPR Therapeutics Inks Collaboration Deal to Develop siRNA Therapies
CRSP enters into a strategic partnership with Sirius Therapeutics for developing novel siRNA Therapies.
CRSPR Stock Could Be Ready to Deliver on Its Massive Promise
Ever since scientists began mapping the human genome, gene editing has always been the end goal. The idea once seemed like something out of a science fiction novel, but it's here today and CRSPR Therapeutics AG NASDAQ: CRSP is leading the way.
CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching CRISPR Therapeutics (CRSP) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
3 Monster Stocks to Hold for the Next 10 Years
The best investments are often stocks of companies offering goods and services that are perpetually in demand. Think entertainment, healthcare, or more recently, some consumer technologies.
Brokers Suggest Investing in CRISPR Therapeutics (CRSP): Read This Before Placing a Bet
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
